Evidence reviews
The following documents contain the evidence that was used to develop the 2024 recommendations:
- A: accuracy and clinical and cost-effectiveness of spirometry for diagnosis of asthma
- B: accuracy and clinical and cost-effectiveness of bronchodilator response in the diagnosis of asthma
- C: accuracy and clinical and cost-effectiveness of peak expiratory flow in the diagnosis of asthma
- D: accuracy and clinical and cost-effectiveness of skin prick test in children for diagnosis of asthma
- E: accuracy and clinical and cost-effectiveness of serum IgE measures in diagnosing asthma in children
- F: accuracy and clinical and cost-effectiveness of FeNO in the diagnosis of asthma
- G: diagnostic accuracy of eosinophil blood count measures in the diagnosis of asthma
- H: bronchial challenge with histamine and methacholine for the diagnosis of asthma
- I: bronchial challenge test with mannitol
- J: bronchial challenge testing in response to exercise for the diagnosis of asthma
- K: accuracy and clinical and cost-effectiveness of combination tests for diagnosis in people with suspected asthma
- L: symptoms diary for monitoring asthma
- M: pulmonary function monitoring in asthma
- N: FeNO measures to monitor asthma
- O: risk stratified care for people with asthma
- P: drug classes for initial asthma management
- Q: drug combinations and sequencing for asthma management
- R: smart inhalers
The following document contains the evidence that was used to develop the 2020 recommendations:
The following documents contain the evidence that was used to develop the 2017 recommendations:
These documents preserve evidence reviews and committee discussions for areas of the guideline that were not updated in 2020.
These documents include the 2017 evidence reviews and committee discussions and have not been updated.
Other supporting evidence
- Economic models
- Methodology
This page was last updated: